Table 1.
n/N (%) with NNRTI mutations | p-value | |
---|---|---|
| ||
Age when tested: | ||
≤8 weeks | 18/21 (85.7) | |
9–16 weeks | 39/53 (73.6) | |
17–26 weeks | 12/21 (57.1) | |
27–39 weeks | 9/25 (36.0) | |
40–52 weeks | 7/12 (58.3) | |
53–78 weeks | 3/12 (25.0) | |
>78 weeks | 0/11 (0.0) | <0.001 |
| ||
Sex: | ||
Male | 35/70 (50.0) | |
Female | 53/85 (62.4) | 0.12 |
| ||
Plasma HIV RNA (copies/ml): | ||
≤100,000 | 11/16 (68.8) | |
100,001 – 1,000,000 | 26/52 (50.0) | |
1,000,000 – 10,000,000 | 35/61 (57.4) | |
>10,000,000 | 9/13 (69.2) | 0.43 |
| ||
CD4%: | ||
<15 | 25/42 (59.5) | |
15–25 | 22/47 (46.8) | |
≥ 25 | 36/59 (61.0) | 0.30 |
| ||
Any breastfeeding: | ||
Yes | 27/53 (50.9) | |
No | 60/100 (60.0) | 0.28 |
| ||
Maternal antiretroviral regimen: | ||
cART§ | 24/28 (85.7) | <0.001* |
Zidovudine/nevirapine | 34/78 (43.6) | |
Zidovudine alone | 17/23 (73.9) | |
Nevirapine alone | 5/9 (55.5) | |
None | 8/17 (47.1) | |
| ||
Infant prophylaxis: | ||
Nevirapine alone (1) | 83/129 (64.3) | |
Zidovudine/nevirapine (2) | 4/21 (19.0) | <0.001** |
Zidovudine alone | 0/1 | |
None | 1/4 (25.0) | |
| ||
Duration of infant nevirapine prophylaxis:*** | ||
<4 weeks | 7/22 (31.8) | |
4–5 weeks | 13/24 (54.2) | |
6 weeks | 48/76 (63.2) | |
>6 weeks | 11/15 (73.3) | 0.04 |
14 women received efavirenz-based, 11 women nevirapine-based and 3 women ritonavir-boosted lopinavir-based therapy.
compares cART to all other groups combined.
compares groups 1 and 2; association is attenuated (p=0.18) if adjusted for child age when tested.
excludes 13/150 children with nevirapine exposure who were missing duration data; association is attenuated (p=0.08) if adjusted for child age when tested.